Scienture Holdings, Inc. is a specialty pharmaceutical company that develops and commercializes treatments for cardiovascular and central nervous system diseases. The company markets two FDA-approved commercial products—Arbli, an oral liquid losartan formulation for hypertension and diabetic nephropathy, and Rezenopy, a naloxone nasal spray for opioid overdose reversal—while maintaining a pipeline of novel candidates addressing migraine, post-surgical pain, thrombotic catheter management, and other unmet medical needs. Scienture generates revenue through direct product sales to wholesalers, specialty pharmacies, and hospitals, along with milestone and royalty payments from licensing partnerships, and contracts with third-party manufacturers for production while maintaining its own patent portfolio to protect its formulations and intellectual property.